PCRX VS MRUS Stock Comparison

Performance

PCRX
10/100

PCRX returned -42.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

MRUS
100/100

MRUS returned 30.77% in the last 12 months. Based on SPY's performance of 15.17%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

PCRX
67/100

16 analysts offer 12-month price targets for PCRX. Together, they have an average target of 57.5, the most optimistic target put PCRX at 63 within 12-months and the most pessimistic has PCRX at 52.

MRUS
85/100

5 analysts offer 12-month price targets for MRUS. Together, they have an average target of 30, the most optimistic target put MRUS at 30 within 12-months and the most pessimistic has MRUS at 30.

Technicals

PCRX
21/100

PCRX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

MRUS
93/100

MRUS receives a 92 of 100 based on 14 indicators. 12 are bullish, 0 are bearish.

Earnings

PCRX
10/100

PCRX has missed earnings 8 times in the last 20 quarters.

MRUS
10/100

MRUS has missed earnings 8 times in the last 20 quarters.

Profit

PCRX
55/100

Out of the last 20 quarters, PCRX has had 12 profitable quarters and has increased their profits year over year on 8 of them.

MRUS
10/100

Out of the last 20 quarters, MRUS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

PCRX
45/100

PCRX has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

MRUS
51/100

MRUS has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

Sentiment

PCRX

"Sentiment" not found for PCRX

MRUS
71/100

MRUS had a bullish sentiment score of 70.74% across Twitter and StockTwits over the last 12 months. It had an average of 1.33 posts, 0.00 comments, and 0.00 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Pacira BioSciences, Inc. Common Stock Summary

Nasdaq / PCRX

Healthcare

Drug Manufacturers - Specialty & Generic

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Merus N.V. Common Shares Summary

Nasdaq / MRUS

Healthcare

Biotechnology

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Power up your portfolio